Corbus Pharmaceuticals Holding (CRBP NASDAQ) stock market data APIs
$8.5109
0.03(0.4%)
as of July 18, 2025
Try our APIs with
free plan!
Corbus Pharmaceuticals Holding Financial Data Overview
Price chart is built with
Anychart
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Prev. Close
8.5109
Open
8.5389
High
8.7986
Low
8.4175
52 wk Range
4.64-61.9
Market Cap
104 M
Shares Outstanding
12 237 K
EPS
-1.3914
Beta
3.117
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Corbus Pharmaceuticals Holding data using free add-ons & libraries
Get Corbus Pharmaceuticals Holding Fundamental Data
Corbus Pharmaceuticals Holding Fundamental data includes:
- Net Revenue:
- EBITDA: -57 240 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: -1.0729
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Corbus Pharmaceuticals Holding News
New
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab
Combination cohort initiated following successful review of monotherapy cohortOver 100 participants dosed to-date in monotherapy cohortPriority are Head and Neck Squamous Cell Carcinoma (HNSCC) and ce...
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium
NORWOOD, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive O...
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
NORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Of...
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rac...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
